US pharma major Bristol-Myers Squibb (NYSE: BMY) has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Opdivo (nivolumab).
This brings Canadian patients with advanced, difficult-to-treat cancers closer to accessing one of the world’s leading immuno-oncology treatments.
The agreement will benefit those living with metastatic melanoma, locally advanced or metastatic pre-treated non-small cell lung cancer (NSCLC) and advanced or metastatic pre-treated renal cell carcinoma (RCC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze